Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
about
sameAs
Evolving paradigms in the treatment of opioid-induced bowel dysfunctionClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionOpioid-induced constipation: pathophysiology, clinical consequences, and management.Recent developments: management of pain.Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in micemicro-Opioid receptor stimulation in the medial subnucleus of the tractus solitarius inhibits gastric tone and motility by reducing local GABA activity.The effects of daikenchuto (DKT) on propulsive motility in the colon.N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonistsOpioid receptors in the gastrointestinal tract.Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in miceAlvimopan Use, Outcomes, and Costs: A Report from the Surgical Care and Outcomes Assessment Program Comparative Effectiveness Research Translation Network Collaborative.New approaches to the treatment of opioid-induced constipation.6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.Does alvimopan enhance return of bowel function in laparoscopic gastrointestinal surgery? A meta-analysis.Pain or constipation: A difficult choice.Opioid-induced bowel dysfunction.Controlling postoperative ileus by vagal activation.Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.
P2860
Q26777692-C65E7862-CBF2-4270-B98C-AA4AD7C0EDE9Q26995944-BA85407B-DBB3-4BA0-BE2F-9D38B70AB8CAQ33635040-9AB11E78-8A8D-4EBF-BF9B-E4DE10903EA3Q33814370-CB6CA53C-E6C8-4AA3-89C5-6EE9ECEB8457Q33814735-E52EEA6C-A435-4F9F-A74C-C5E694178B66Q34085287-CC8A26F1-BAE5-45BC-884D-984CE083162DQ34154657-C1170D9C-8D36-40D4-BA33-815695D050EAQ34478208-E9C95986-0ADF-4C86-9321-758D67D1C76FQ35185222-9223DEDE-DC92-4697-95A8-DB92090DB00CQ36178704-B173DA7C-FF09-4751-A146-6D82BA68089FQ36845583-CBE6863E-8E28-4F53-85D9-C8DC9CC6619EQ37299608-6C155A5F-A9F8-4530-B538-CAA9501F2307Q37444418-197EE391-06A3-4C01-92BE-967E5609CDCBQ38958130-EDDB1BD4-028F-4C21-BD62-88FF4304B719Q42110210-EC8FF596-2F8B-48F0-8DE0-183773707CE6Q42323281-627175A7-9145-43F0-9204-FFB9D546F776Q42843853-DF503897-FD11-487C-A9FC-4773B66B0F53Q43314925-4CCA2700-23A2-4515-9CEE-9BD2B549F840
P2860
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@ast
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@en
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@nl
type
label
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@ast
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@en
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@nl
prefLabel
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@ast
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@en
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@nl
P1476
Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist
@en
P2093
W K Schmidt
P304
P407
P433
P577
2001-11-01T00:00:00Z